Genetic Function – Page 3

Astellas Expands Gene Therapy Portfolio with $2.2 Billion Deal for AviadoBio’s Frontotemporal Dementia Treatment

7 months ago talkbio0Tagged Astellas Pharma Inc., AVB-101, AviadoBio Ltd., Frontotemporal dementia, gene therapy, Mutation, Neurodegenerative Disorders, Pick Disease of the Brain, Progranulins

Astellas Pharma Inc., AviadoBio Ltd., Gene Therapy, Frontotemporal Dementia, FTD-GRN, AVB-101, Progranulin Mutations, Neurodegenerative Diseases

RNAi Revolution: Former Alnylam Team Launches $135M siRNA Engineering Startup

7 months ago talkbio0Tagged Alnylam, Cities, Genetic Engineering, RNA Interference, RNA, Small Interfering

RNAi, siRNA, Alnylam, City Therapeutics, John Maraganore, genetic engineering, biotech startup

Black Diamond Therapeutics Refocuses on Lung Cancer Drug BDTX-1535 Amid Workforce Reduction

7 months ago talkbio0Tagged BDTX-1535, Black Populations, Diamond Therapeutics, Epidermal Growth Factor Receptor, Malignant neoplasm of lung, Mutation, Protein-tyrosine kinase inhibitor, Tagrisso

Black Diamond Therapeutics, workforce reduction, lung cancer drug, BDTX-1535, EGFR mutations, Tagrisso, tyrosine kinase inhibitor

FDA Panel Recommends Limiting Immunotherapy Access for Stomach and Esophageal Cancer Patients Based on PD-L1 Expression

7 months ago talkbio0Tagged Esophageal Neoplasms, Gene Expression, Immunotherapy, Keytruda, Malignant neoplasm of stomach, PD-L1, Tevimbra, United States Food and Drug Administration

FDA, Immunotherapy, Stomach Cancer, Esophageal Cancer, PD-L1 Expression, Keytruda, Opdivo, Tevimbra

FDA Considers Restricting PD-1 Drugs in Stomach and Esophageal Cancers Based on PD-L1 Expression

7 months ago talkbio0Tagged Esophageal Neoplasms, Gene Expression, nivolumab, PD-L1, PDCD1 gene, pembrolizumab, restrictions, tislelizumab, United States Food and Drug Administration

PD-1 drugs, stomach cancer, esophageal cancer, PD-L1 expression, FDA restrictions, pembrolizumab, nivolumab, tislelizumab

FDA Advisory Panel Rejects PD-1 Inhibitors for Gastric and Esophageal Cancers with Low PD-L1 Expression

7 months ago talkbio0Tagged Biological Markers, Drug Approval, Esophageal Neoplasms, Gene Expression, inhibitors, Malignant neoplasm of stomach, Neoplasms, PD-L1, PDCD1 gene, United States Food and Drug Administration

FDA, PD-1 inhibitors, gastric cancer, esophageal cancer, PD-L1 expression, biomarker, oncology, drug approval

Transforming Multiple Sclerosis Treatment: Emerging Trends and Future Directions

7 months ago talkbio0Tagged Artificial Intelligence, disease-modifying therapies, DNA Integration, Hemopoietic stem cell transplant, High-Efficacy, Multiple Sclerosis, myelin repair, neurorestorative, Precision Medicine

Multiple sclerosis, high-efficacy treatments, stem cell transplantation, disease-modifying therapies, personalized medicine, AI integration, myelin repair, neurorestorative therapies.

Wave Life Sciences Reports Positive Interim Data for Duchenne Muscular Dystrophy Treatment

7 months ago talkbio0Tagged Clinical Trials, DMD, Does skip, Duchenne, Dystrophin, exon 53, FORWARD-53, Gene Expression, Interim, Muscular Dystrophy, Muscular Dystrophy, Duchenne, Wave Life Sciences, WVE-N531

Wave Life Sciences, Duchenne Muscular Dystrophy, DMD, Exon 53 Skipping, WVE-N531, FORWARD-53 Clinical Trial, Interim Data, Muscle Health, Dystrophin Expression